Convergent Genomics

Executive Summary

Convergent Genomics is a San Diego-based molecular diagnostics company founded in 2018 with a mission to simplify and accelerate cancer diagnostics. The company focuses on urologic cancers, starting with bladder cancer, through its proprietary UroAmp urine test. UroAmp is a non-invasive, genomic-based assay designed to detect and monitor bladder cancer by analyzing urine samples for tumor-specific genetic alterations. By providing clinicians and patients with personalized, actionable insights, Convergent Genomics aims to improve early detection, reduce invasive procedures, and enable more effective treatment monitoring. Bladder cancer is one of the most expensive cancers to manage due to frequent surveillance cystoscopies, and a highly accurate urine test could significantly reduce healthcare costs while improving patient compliance and outcomes. The company operates in the rapidly growing liquid biopsy market, which is increasingly recognized for its potential in early cancer detection and recurrence monitoring. While Convergent Genomics has not disclosed its funding stage or total raised, its differentiated focus on urologic cancers and a non-invasive sampling method positions it well within the competitive landscape. Key challenges include regulatory clearance, clinical validation, and market adoption against established players. However, the clinical need for a reliable, non-invasive alternative to cystoscopy is clear. With a strong IP portfolio and strategic positioning, Convergent Genomics is poised to capitalize on the shift toward precision medicine in urology, assuming successful commercialization and clinical utility demonstration.

Upcoming Catalysts (preview)

• TBDFDA 510(k) clearance or breakthrough device designation for UroAmp40% success
• TBDPublication of pivotal clinical study results demonstrating sensitivity/specificity of UroAmp60% success
• TBDPartnership or distribution agreement with a urology reference laboratory or hospital network50% success